Corrigendum to: Antiproliferative Activity of Cephalotaxus Esters: Overcoming Chemoresistance

作者：Vladimir Yong‐Gonzalez, Constantin Radu, Paul Calder, David Ho-Keung Shum, Mark G. Frattini, Hakim Djaballah · 发表于：Combinatorial Chemistry & High Throughput Screening · 年份：2025 · DOI：10.2174/138620732816250902170439 · 研究领域：Biological Activity of Diterpenoids and Biflavonoids、Synthesis of Organic Compounds、Synthesis and biological activity

It has been brought to our attention that a deceased individual was inadvertently included as a co-author of this article. In line with publishing policies and ethical guidelines, the corresponding author has been advised to remove their name from the author list. Their valuable contributions to the work will be appropriately recognized in the Acknowledgements section. The original article can be found online at https://benthamscience.com/public/article/144076 Details of the correction: • Original: 1HTS Core Facility - Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; 2Molecular Pharmacology Program - Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; 3Department of Medicine - Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; 4Molecular Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; 5Deceased; 6Department of Analytical Chemistry, C16 Biosciences, New York, NY 10019, USA; 7Automation and Workflow Solutions, Molecular Devices, San Jose, CA 95134, USA; 8Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; 9Screening Discovery Platform, Institut Pasteur Korea, Seongnamsi, Gyeonggido, 13488, Republic of Korea; 10Office of the CMO, Cellectis Inc, New York, NY 10016, USA; 11Office of the CEO, Keren Therapeutics, New York, NY 10583, USA • Corrected: 1HTS Core Facility - Memorial Sloan Kettering Can...